GPC3-targeted PET/CT for detecting liver cancer
Part of Cancer, Digestive system clinical trials.
This study uses a special PET/CT scan that targets a protein (GPC3) found in liver cancer cells. The goal is to see how well it can detect or track liver cancer, whether it's newly diagnosed or has been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have, or be suspected to have, hepatocellular carcinoma (a type of liver cancer, confirmed by imaging or biopsy).
- You must be willing and able to give informed consent (or have a parent or legal representative do so).
- Your doctor must expect you to live at least 3 more months and you must be able to follow study procedures and visits.
- You must be able to complete a PET/CT scan (a special imaging test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of imaging scan (called 68Ga-NYM207 PET/CT) that may help doctors better find and understand liver cancer. You would receive the scan once to see if it helps doctors plan your treatment or monitor your cancer.
This trial tests a new treatment called CAR-T cells that are designed to find and attack liver cancer cells with a specific marker (GPC3). If you have advanced hepatocellular carcinoma (liver cancer) that has not responded to standard treatments, this study may be an option to explore.
This trial tests a new type of immune cell therapy called Metabolically Armed GPC3 CAR-T cells (Meta10-GPC3) for people with liver cancer that has come back or spread and cannot be removed by surgery. The cells are designed to target a protein called GPC3 on cancer cells and may help shrink tumors.
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.